Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus

被引：323
|
作者：
Cui, LZ
Tominaga, E
Neoh, HM
Hiramatsu, K
机构：
[1] Juntendo Univ, Fac Med, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan
[2] Juntendo Univ, Fac Med, Dept Infect Control Sci, Bunkyo Ku, Tokyo 1138421, Japan
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 03期
关键词：
D O I：
10.1128/AAC.50.3.1079-1082.2006
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We present here findings of a strong positive correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus (VISA). This correlation is related to cell wall thickening, suggesting that, similar to the case with vancomycin resistance in VISA, the physical barrier of a thickened cell wall may contribute to daptomycin resistance in S. aureus.
引用
收藏
页码：1079 / 1082
页数：4
相关论文
共 50 条
  • [21] A Novel δ-Hemolysis Screening Method for Detecting Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate S-aureus
    Cafiso, V.
    Bertuccio, T.
    Spina, D.
    Purrello, S.
    Blandino, G.
    Stefani, Stefania
    JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (05) : 1742 - 1744
  • [22] Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid
    Saravolatz, Louis D.
    Pawlak, Joan M.
    Wegner, Corinne
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2605 - 2608
  • [23] DIFFERENTIAL INFLAMMATORY RESPONSES IN MACROPHAGES BY VANCOMYCIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS AND VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS
    Lee, H. -S.
    Kuo, T. -Y.
    INFLAMMATION RESEARCH, 2011, 60 : 159 - 159
  • [24] Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia
    Naimi, TS
    Anderson, D
    O'Boyle, C
    Boxrud, DJ
    Johnson, SK
    Tenover, FC
    Lynfield, R
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) : 1609 - 1612
  • [25] The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC
    Chen, Hongbin
    Liu, Yudong
    Sun, Wenjia
    Chen, Minjun
    Wang, Hui
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2011, 71 (03) : 301 - 303
  • [26] Staphylococcus aureus with reduced susceptibility to vancomycin
    Cosgrove, SE
    Carroll, KC
    Perl, TM
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (04) : 539 - 545
  • [27] Reduced Susceptibility to Vancomycin in Staphylococcus aureus
    Mimica, Marcelo J.
    EMERGING INFECTIOUS DISEASES, 2011, 17 (11) : 2083 - 2084
  • [28] Septic arthritis caused by vancomycin-intermediate Staphylococcus aureus
    Lu, JJ
    Lee, SY
    Hwa, SY
    Yang, AH
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4156 - 4158
  • [29] Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure
    Kelley, Peter G.
    Gao, Wei
    Ward, Peter B.
    Howden, Benjamin P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) : 1057 - 1060
  • [30] Selection of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus by Imipenem
    Katayama, Yuki
    Murakami-Kuroda, Hiroko
    Cui, Longzhu
    Hiramatsu, Keiichi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) : 3190 - 3196
12345